When discussing about cannabis, many ASX listed pot stocks come into picture. One such stock that has done well in the past is AusCann Group Holdings Limited (ASX: AC8). AusCann Group is into manufacturing and cultivation, supply of medical cannabis products. The Company focuses on investigating opportunities in the medical cannabis sector, including acquisition or investment in other international plant breeders, producers and suppliers. They believe Australian patients have the right to access high quality, cost effective, cannabinoid medicines.
In an attempt to achieve this and to enhance the reach in market, AusCann snapped up an agreement with Australian Pharmaceutical Industries Limited (ASX:API). API is a well-known wholesaler of pharmaceutical products in Australia, and will help AC8 to enhance the distribution setup. Further, AusCann has a tie up with Tasmanian Alkaloids, and both the groups have been working on processes to produce final dosage form of cannabinoid pharmaceuticals that can be distributed into the domestic and international markets. AusCann is thus trying to scale up its existing medical liaison team with more emphasis on the educational programs being targeted for the doctors in cannabinoid medicine. The group’s joint venture in Chile has been on track with few harvesting updates.
Lately, AC8 bagged a research and development agreement with Canadian Group Jade Cannabis, which will help in the development and optimisation of the AusCann cannabis cultivation system. This news has come after the recent update from AC8 on completion of second harvest in Chile. Thus, the group is expediting its operations in all key jurisdictions.
AusCann (ASX: AC8) traded at a market price of $1.250 as at June 27, 2018 but was seen to be moving down by 3% on June 28, 2018 during early trading hours. It has seen a performance change of a staggering 236.84% over the past 12 months. The stock price changed from $0.360 as at June 26, 2017 to $1.280 as at June 26, 2018. The 52 weeks low for the stock has been $0.360 and 52 weeks high for the stock is $1.860. The company has an Earnings per share of -0.009 AUD. However, despite the boost in the cannabis sector with Canada moving an inch up on legalization of use of small amounts of cannabis for recreational purposes by adults and US FDA approving the first cannabis based drug, AC8 has fallen about 20.99% in last three months, as at June 27, 2018. This has been owing to the speculative future of cannabis. Along with AC8, many other pot stocks have also taken a back footing recently. Amidst this, AusCann was seen to surge up to more than 14 per cent to reach $1.23 after a big drop in the share price and large trading volumes when the news of the latest partnership broke.
For its Tasmanian facility, Canadian developed, state of the art, Argus Controls systems and Conviron cannabis are put in place to grow rooms. To support the cultivation operation, AusCann is developing a suite of proprietary advanced analytics. These analytics will be refined and deployed as part of the research engagement with Jade Cannabis. With expansion plans in Canada and Australia, and boost from the legalization of recreational cannabis in Canada, AC8 remains a stock to stick to at the current price of $ 1.235. While many pot stocks have emerged lately and are yet to report profits, the key to success would be resilient fundamentals and partnerships with a support from capabilities to explore global export opportunities. Looking at this, AusCann is one stock striving to achieve better performance despite the volatility in the sector.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkine.com.au and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). The information on this website has been prepared from a wide variety of sources, which Kalkine Pty Ltd, to the best of its knowledge and belief, considers accurate. You should make your own enquiries about any investments and we strongly suggest you seek advice before acting upon any recommendation. Kalkine Pty Ltd has made every effort to ensure the reliability of information contained in its newsletters and websites. All information represents our views at the date of publication and may change without notice. To the extent permitted by law, Kalkine Pty Ltd excludes all liability for any loss or damage arising from the use of this website and any information published (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine Pty Ltd hereby limits its liability, to the extent permitted by law to the resupply of services. There may be a product disclosure statement or other offer document for the securities and financial products we write about in Kalkine Reports. You should obtain a copy of the product disclosure statement or offer document before making any decision about whether to acquire the security or product. The link to our Terms & Conditions has been provided please go through them and also have a read of the Financial Services Guide. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.